MoonLake Immunotherapeutics

NASDAQ:MLTX

Biotechnology

Healthcare
$10.79 +0.69%

+$0.13 today

Market cap
$918.30M
Beta
1.04
P/E (TTM)
-5.4
EPS (TTM)
-$3.61
52W Low $5.95High $62.75

Volume 1.32M

Average 0.99M

MLTX Operating Cash Flow

Cash generated by the company's core business operations during the period.

MoonLake ImmunotherapeuticsNASDAQ: MLTX

Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Operating cash flow growth accelerates

Q1 FY2026 operating cash flow of $66.29M (cash outflow) rose 73.8% year over year, ahead of the +60.4% change in trailing-twelve-month operating cash flow. Sequentially, it rose 12.7% from the prior quarter. Over 3 fiscal years it compounded at +51.9% a year.

Context

  • Operating cash flow grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +73.8% holds above the trailing-twelve-month pace of +60.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$66.29M+12.7% QoQ
Last fiscal yearDec 2025
-$196.01M+68.1% YoY
LTMMar 2026
-$224.15M+60.4% YoY
Operating Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+73.8%——
1 year+68.1%——
3-year CAGR+51.9%——
5-year CAGR——
10-year CAGR——

Operating Cash Flow history

USD · from the cash flow

Latest · FY2025
(196.01M) USD
Year-over-year change
-68.1%

Operating Cash Flow vs competitors

How MLTX compares with its peers on the latest reported figures

  • MLTX's LTM Mar 2026 operating cash flow of $224.15M is the 3rd largest of the 11 companies compared; the peer median is $55.7M.
  • Its year-over-year change of +60.4% is the 7th highest of 11, against a peer median of +86.5%.
  • Over three fiscal years its annual growth of +51.9% compares with a peer median of +44.2%.
MLTX Competitors Peer median
Operating Cash Flow for MLTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NRIXNurix Therapeutics, Inc.LTM Aug 2026$379.31M +264.6%+16.0%54.0%
ALMSAlumis Inc. Common StockLTM Jun 2026$351.4M +1.8%+50.8%4749.9%
MLTXMoonLake ImmunotherapeuticsLTM Mar 2026$224.15M +60.4%+51.9%—
DNTHDianthus Therapeutics, Inc.LTM Jun 2026$155.38M +55.0%+64.4%8160.5%
ORKAOruka Therapeutics, Inc.LTM Sep 2026$123.64M +46.4%+100.7%—
ZURAZura Bio LimitedLTM Mar 2026$72.68M +112.8%+277.8%—
ATTOAttovia Therapeutics, Inc.FY2025$59.2M +69.0%—4385.1%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$52.21M +323.8%-11.3%623.9%
CNTBConnect Biopharma Holdings LimitedFY2025$51.21M +116.9%-19.8%80009.4%
EQEquillium, Inc.LTM Mar 2026$18.88M +2.6%+37.6%—
ANABAnaptysBio, Inc.LTM Mar 2026$4.48M +104.1%—1.9%
Peer median (excluding MLTX) $55.7M+86.5%+44.2%4385.1%

Competitors are the stored peer set for MLTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(53.64M)(49.97M)(44.08M)(121.24M)(229.1M)
Depreciation & Amortization4.97K12.36K13.16K1.38M2.62M
Deferred Income Tax00000
Stock-Based Compensation10.86M9.65M7.11M7.28M12.9M
Change in Working Capital4.48M(1.43M)(6.22M)(3.78M)19.88M
Accounts Receivables(148.77K)(68.36K)(840K)(1.79M)(2.03M)
Inventory00000
Accounts Payables1.57M(1.31M)000
Other Working Capital3.06M(44.8K)(6.22M)(2M)21.9M
Other Non-Cash Items13.98M(4.51M)399.51K(225.71K)(2.3M)
Operating Cash Flow(35.18M)(55.89M)(42.78M)(116.59M)(196.01M)
Capital Expenditures(50.71K)(16.01K)(284.63K)(519.52K)(35K)
Acquisitions (Net)00000
Purchases of Investments0(42.23M)(175.73M)(350.28M)(265.37M)
Sales of Investments09.9M150.83M145.2M468.4M
Other Investing Activities00000
Investing Cash Flow(50.71K)(32.34M)(25.18M)(205.6M)202.99M
Debt Repayment15M(15M)0073.02M
Common Stock Issued28.27M3.79K482.45M52.54M72.98M
Common Stock Repurchased(6.2K)00(50)0
Dividends Paid00000
Other Financing Activities0134.69M(2.75M)(1.23M)0
Financing Cash Flow43.26M119.69M479.7M51.31M146M
Effect of Forex Changes(1.33M)8.54K(75.31K)127.97K1.11M
Net Change in Cash6.7M31.47M411.66M(270.74M)154.09M
Free Cash Flow(35.23M)(55.91M)(43.06M)(117.11M)(196.04M)

MoonLake Immunotherapeutics

NASDAQ:MLTX

Intrinsic Alpha fair value

Locked

Current Price

$10.79

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.